Skip to main content
. 2020 Jun 24;16:1744806920934998. doi: 10.1177/1744806920934998

Figure 1.

Figure 1.

Scratching bouts (a) and alloknesis score (b) in IMQ treated-mice on day 7, ****P < 0.0001, n = 10 (male = 5, female = 5) mice per group. (c) Immunofluorescence showing the expression of IBA-1 and GFAP in spinal cord dorsal horn (C3–C4) in IMQ- and vehicle-treated mice after seven days treatment. Scale bars, 100 µm, 10 µm in insert. Quantitative analysis of IBA-1 (d) and GFAP (e) immuofluorescence intensity of IMQ- and vehicle-treated mice after seven days treatment. **P < 0.01, n = 5 (male = 3, female = 2) mice per group. (f) Immunofluorescence showing the expression of IBA-1 in spinal cord dorsal horn (C3-C4) in IMQ- treated male and female mice after seven days treatment, n = 4 mice per group. Scale bars, 100 µm. (g) Quantitative analysis of IBA-1 immuofluorescence intensity in male and female mice after seven days treatment, n = 4 mice per group. n = 4 mice per group. (h) Immunofluorescence showing the expression of IBA-1 in saline-, minocycline-, and PLX5622-treated male mice. Scale bars, 100 µm. Scratching bouts (i) and alloknesis score (j) in saline-, minocycline-, and PLX5622-treated mice after seven days IMQ treatment,*P < 0.05; **P < 0.01; ****P < 0.0001, n = 10 (male = 5, female = 5) mice in saline- and minocycline-treated per group, n= 4 (male =2, female = 2) mice in PLX5622- treated group. (k) Quantitative analysis of IBA-1 immuofluorescence intensity in saline-, minocycline-, and PLX5622-treated mice. **P < 0.01, n = 4 (male =2, female = 2) mice per group. Scratching bouts (l) and alloknesis score (m) in male and female mice after IMQ treatment. *P < 0.05; **P < 0.01, n = 7 mice per group. Data are presented as means ± SEM, Student’s t test or two-way ANOVA.